Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Trillium Therapeutics Inc. (NASDAQ: TRIL).

Full DD Report for TRIL

You must become a subscriber to view this report.


Recent News from (NASDAQ: TRIL)

Trillium Therapeutics Announces Data Presentations at Upcoming Scientific Meetings
Updated safety and efficacy data from the TTI-621 intravenous trial at the 16th Annual Discovery on Target Conference Updated data from the TTI-621 intralesional trial in patients with mycosis fungoides and Sézary Syndrome at the EORTC CLTF 2018 Meeting TORONTO, Sept. 1...
Source: GlobeNewswire
Date: September, 12 2018 07:00
Trillium to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
TORONTO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that it will be featured as a presenting company at the 20 th Annual Rodman &...
Source: GlobeNewswire
Date: August, 30 2018 09:30
FDA OKs Kyowa Kirin's mogamulizumab for two rare types of lymphoma
The FDA approves Kyowa Kirin's Poteligeo (mogamulizumab-kpkc) for the treatment of adults with relapsed/refractory mycosis fungoides or Sézary syndrome after at least one prior line of systemic therapy. It is the first drug approved in the U.S. for the latter. Both are rare forms of c...
Source: SeekingAlpha
Date: August, 08 2018 11:49
Trillium Therapeutics Reports Second Quarter 2018 Financial and Operating Results
Increased focus on T cell lymphoma in lead program, TTI-621 Initiated dosing of TTI-622 (SIRPaFc IgG4) in phase 1a/1b clinical trial Recruited Dr. Yaping Shou as Chief Medical Officer Negotiated improved SIRPaFc license agreement TORONTO, Aug. 08, 2018 (GLOBE NEWSW...
Source: GlobeNewswire
Date: August, 08 2018 07:00
47 Scoop: Trillium Bleeds, Surface Hemorrhages, And Forty Seven Throws In The $47 Million Towel On Synthon Lawsuit
CD47, a novel immune checkpoint in the innate immune system, is a rapidly emerging target in cancer immunotherapy. Previously, I spoke to the merits of the technology and the key drivers fueling a cohort of 8 companies developing CD47-directed therapies. Today, I provide updated commentary o...
Source: SeekingAlpha
Date: August, 01 2018 16:46

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-146.706.406.756.2546117,033
2017-03-106.006.006.105.9621,174
2017-03-096.006.006.255.8043,570
2017-03-085.806.156.255.767379,990
2017-03-075.705.755.8845.50534,666

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-112,40017,15813.9876Cover
2018-12-1039,83768,72457.9666Short
2018-12-073,60418,50419.4769Cover
2018-12-0614,10046,24530.4898Cover
2018-12-0412,66645,38127.9104Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TRIL.


About Trillium Therapeutics Inc. (NASDAQ: TRIL)

Logo for Trillium Therapeutics Inc. (NASDAQ: TRIL)

Trillium Therapeutics Inc. is an immuno oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRPaFc and a CD monoclonal antibody mAb , which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody like fusion protein that blocks the activity of CD , a molecule that is upregulated on tumor cells in acute myeloid leukemia AML and numerous other malignancies. The CD mAb is a fully human monoclonal antibody that blocks the activity of CD , an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors.

 

 

 

Current Management

  • Niclas Stiernholm / CEO
  • James Parsons / CFO
  • Penka Petrova / VP, Drug Dev.
  • Bob Uger / Chief Scientific Officer
  • Luke Beshar /
  • Henry Friesen /
  • Robert Kirkman /
  • Michael Moore /
  • Thomas Reynolds /
  • Niclas Stiernholm /
  • Calvin Stiller /

Current Share Structure

  • Market Cap: $26,879,479 - 05/18/2018
  • Issue and Outstanding: 4,266,584 - 11/20/2014

 


Recent Filings from (NASDAQ: TRIL)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: September, 12 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 08 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 25 2018
Voluntary supplemental materials filed by foreign issuers under Section 11(a) of the 1933 Act
Filing Type: SUPPLFiling Source: edgar
Filing Date: June, 20 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 20 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 20 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 18 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 14 2018

 

 


Daily Technical Chart for (NASDAQ: TRIL)

Daily Technical Chart for (NASDAQ: TRIL)


Stay tuned for daily updates and more on (NASDAQ: TRIL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: TRIL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TRIL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TRIL and does not buy, sell, or trade any shares of TRIL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/